Fig. 7: Improved anti-tumor effect of LV::UBA7-27 when combined to an antagonistic anti-PD1 treatment. | npj Vaccines

Fig. 7: Improved anti-tumor effect of LV::UBA7-27 when combined to an antagonistic anti-PD1 treatment.

From: Optimized lentiviral backbone induces robust and diverse T cell immunity against neoantigens to counteract tumor heterogeneity

Fig. 7: Improved anti-tumor effect of LV::UBA7-27 when combined to an antagonistic anti-PD1 treatment.

C57BL6/J mice were injected s.c. with 2.5 × 105 MC38 WT at day 0 and were then injected i.m. with 1 × 109 TU per mouse of Ctrl LV or LV::UBA7-27 at day 6 (n = 7). Mice were injected i.p. with 200 µg of either αPD1 antibody or an isotype control (iso) at day 9 and then twice a week for 3 weeks. a Experiment timeline. b Tumor growth curves. Red line = the time point of LV injection. Gray area = antibody treatment interval. c Kaplan–Meier survival curves. d Tumor size at the end of αPD1 or iso treatment (day 29). Statistical significance was determined using a log-rank test (c) or a one-way ANOVA test (d). * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001).

Back to article page